<DOC>
	<DOCNO>NCT01267201</DOCNO>
	<brief_summary>A new formulation methylprednisolone develop . A study need determine drug availability use new formulation , powder reconstitution suspension , versus current commercially available tablet formulation healthy volunteer .</brief_summary>
	<brief_title>A Study Comparing Drug Availability Of Methylprednisolone In Liquid Form Versus Methylprednisolone In Tablet Form</brief_title>
	<detailed_description />
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Body Mass Index ( BMI ) 17.5 30.5 kg/m2 ; total body weight &gt; 45 kg ( 99 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic disease ; Any condition possibly affect drug absorption ( eg , gastrectomy ) .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Single dose bioavailability study methylprednisolone powder oral suspension ( 4mg/mL ) versus methylprednisolone tablet ( 32 mg )</keyword>
</DOC>